According to recent guidelines, long-term anticoagulation is recommended for patients with atrial fibrillation (AF) and a risk profile with CHA2DS2-VASc score of 1 or more. Vitamin K antagonists(VAK) and novel oral anticoagulants such as rivaroxaban are current treatment options for AF patients with additional risk factors for stroke. Currently there are only limited information to what extend AF patients prefer one or the other treatment option based on patient relevant characteristics of novel oral anticoagulants vs. VKAs. It is also unknown which of the characteristics influences patient preference most and how this relates to a neutral comparator. Furthermore, an additional unknown factor is also how patient evaluate their current treatment and if this leads to differences among treatment with VKAs and rivaroxaban.

Inclusion Criteria:

A.General Criteria (Group 1and Group2):

• diagnosed non-valvular AF
• older than 18 years
• general capability and willingness to perform a structured patient interview in German
• no participation in any other clinical or observational study over the last 3 month

Additional criteria for Group1 (VKA-experienced):

• active VKA-therapy for at least 3 month without significant interruptions
• in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.

Additional criteria for Group2 (rivaroxaban-experienced patients):

• active rivaroxaban-therapy for at least 3 month without significant interruptions
• in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.

Exclusion Criteria:

• participation in any other clinical or observational study over the last 3 month

Adult AF-patients, within 3 month of anticoagulation (VKA or rivaroxaban) therapy, recruited by GPs